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Invariant TCRαβ-expressing NKT (iNKT) 
cells comprise highly conserved CD4+ and 
CD4−/CD8− (DN) T lymphocyte subsets with 
important immune regulatory functions (1). In 
contrast to conventional MHC class I (pMHC) 
and MHC class II–restricted peptide-specifi c 
TCRαβ cells, iNKT cells specifi cally recognize 
glycosylceramide ligands presented by non-
polymorphic CD1d proteins (2).
α-galactosylceramide (α-GalCer), a glyco-
sylceramide ligand which is not produced by 
mammals, is widely used as a highly specifi c 
antigen for both human and murine iNKT 
cells. In both species, these cells use precisely 
rearranged homologous TCR variable (V)α 
and junctional (J)α segments, namely human 
Vα24/Jα18 and murine Vα14/Jα18, with 
minimal or no N-region additions and almost 
identical CDR3α sequences (3, 4). However, 
neither a specifi c Vα nor Vβ chain is required 
to recognize CD1d protein, since TCRs from 
autoreactive and nonlipid-specifi c CD1d-
 restricted hybridomas use diverse Vα, Jα, and 
Vβ segments (5, 6). Functional studies using 
murine iNKT hybridomas have revealed a high 
degree of iNKT TCR specifi city for the carbo-
hydrate portion of the glycolipid ligand (7). 
Together these facts suggest that the invariant 
CDR3α loop of iNKT TCRs might be di-
rectly involved in recognition of the natural 
CD1d-bound iNKT antigen.
We have previously described α-GalCer–
mediated in vitro expansion of human CD1d–
α-GalCer–specifi c CD4+ and CD8αβ+ T cell 
populations using diverse TCR Vα, Jα, Vβ, 
and Jβ chains, demonstrating that TCR Vα 
segments other than Vα24 can productively 
rearrange with diverse Jα genes to mediate rec-
ognition of CD1d–α-GalCer (8). Interestingly, 
like iNKT cells, the great majority of Vα24- 
 independent CD1d–α-GalCer–specifi c cells 
used polyclonal Vβ11 chains. In addition, in vivo 
 expansion of Vα24-/Vβ11+ CD1d–α-GalCer 
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tetramer–specifi c T lymphocytes was recently  observed in 
 patients with advanced cancer receiving α-GalCer–pulsed 
 autologous dendritic cells (9). However, in the absence of 
 supraphysiological antigenic in vivo or ex vivo stimulation 
these Vα24-independent, Vβ11+ CD1d–α- GalCer–specifi c 
T lymphocytes are extremely rare (9; unpublished data). 
 Several studies have shown that iNKT cells derive from the 
same pool of double-positive precursors as con ventional 
T lymphocytes, arguing strongly in favor of their  antigen-
driven selection (10, 11).
The binding affi  nities of iNKT TCRs and Vα24-
 independent Vβ11+ TCRs to CD1d molecules loaded with 
the natural ligand(s) is not known. However, the observation 
that Vα24-/Vβ11+ CD1d–α-GalCer–specifi c T cells can be 
effi  ciently expanded both in vitro (8) and in vivo (9) by 
α-GalCer stimulation suggests that both types of CD1d–α-
GalCer–specifi c TCRs may have similar binding affi  nities to 
CD1d–α-GalCer complexes.
To address this hypothesis, we isolated a panel of Vα24+ 
(iNKT) and Vα24-Vβ11+, CD1d–α-GalCer–specifi c T cell 
clones and compared the binding of their recombinant solu-
ble T cell receptors to CD1d–α−GalCer monomers. We 
extended these studies by determining the atomic structures 
of the three human TCRs. Based on these results, we suggest 
a docking model for human TCR binding to the CD1d–α-
GalCer complex.
RESULTS
Importance of the CDR3𝛂 loop for recognition 
of CD1d-presented glycolipids
The DN Vα24+/Vβ11+ iNKT clone used for TCR clon-
ing was produced from a previously generated DN iNKT 
line (8). 13 new Vα24−/Vβ11+ CD1d–α-GalCer–specifi c 
T cell clones were generated from a healthy donor, whose 
Vα24−/CD1d–α-GalCer tetramer+ T cells expanded from 
background levels to 5.5% within 3 wk in culture after in vitro
stimulation with α-GalCer. FACS staining of the clones 
 using CD1d–α-GalCer tetramers showed similar intensities 
(Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20052369/DC1). However, these clones exhib-
ited diff erent properties regarding their ability to bind to 
CD1d–α-GalCer monomers and also to express CD4 and 
CD8 coreceptors (Fig. 1). From these 13 Vα24−/Vβ11+ 
T cell clones we chose one CD4+ clone, 5E, which exhib-
ited the strongest monomer binding of all CD4+ clones, as 
well as the CD8αβ+ clone 5B, which showed no detectable 
monomer binding, for molecular cloning of their TCR α 
and β chains.
Sequencing data for the cloned variable chains of the 
three TCRs, iNKT, 5E, and 5B are presented in Fig. 1, 
A and B.[ID]FIG1[/ID] As expected, all three TCRs showed usage of the 
Vβ11 family, with identical CDR1β and CDR2β, but 
 diff erent CDR3β sequences (Fig. 1 B). The Vβ11 gene seg-
ments of iNKT, 5E, and 5B were joined to diff erent Jβ seg-
ments, with various N-region deletions and additions. 
 Sequencing of the cloned Vα chain of iNKT confi rmed the 
expected invariant Vα24s1-Jα18 rearrangement and revealed 
the Vα gene segments used by clones 5E and 5B to be Vα10s1 
and Vα3s1, respectively (Fig. 1 A). Alignment of the Vα 
chain peptide sequences showed 48.9% sequence identity be-
tween Vα24 and Vα3.1, 46% identity between Vα24 and 
Vα10.1, and 44.2% identity between Vα3.1 and Vα10.1 
(unpublished data). Surprisingly, Vα gene segments of 5E 
and 5B were also rearranged to Jα18, resulting in almost 
identical CDR3α loop peptide sequences for the three TCRs 
(Fig. 1 A). In all three TCRs two bases had been removed 
from the 5′ end of the germline Jα18 gene segment, as previ-
ously described for other iNKT TCRs (3). No further N-re-
gion modifi cations were seen at the Vα24s1-Jα18 junctional 
site of our iNKT TCR. In contrast, template-independent 
N-region modifi cations could be observed at the Vα-Jα 
junctions of 5E and 5B. Two N additions were seen at the 3′ 
end of the germline Vα10s1 sequence in 5E, whereas re-
moval of seven bases from the 3′ end of the germline Vα3s1 
sequence as well as insertion of six new nucleotides were 
found in 5B (Fig. 1 A). Hence, the CDR3α peptide se-
quences of iNKT, 5E, and 5B diff ered only with regard to 
the three amino acids immediately after the conserved disul-
fi de bond-forming Cys90. These results strongly argue for an 
antigen-driven selection of the Vα24-independent clones, 
and they suggest an essential role for the CDR3α loop in 
recognition of the polar head group of CD1d bound glyco-
lipid ligands.
Figure 1. Highly similar CDR3𝛂 regions in human V𝛂24-dependent 
and -independent, V𝛃11-positive CD1d–𝛂-GalCer–specifi c TCRs. 
Alignments of the Vα-Jα junctions (A) and the Vβ-Dβ-Jβ junctions 
(B) of dsTCRs iNKT, 5B, and 5E with germline gene sequences are 
shown (underlined lowercase characters, Jα/Jβ genes; capitals, 
variable α/β genes; bold lowercase characters, template-independent 
N-region modifications; italic capitals, Dβ genes; bold capitals, 
CDR3α/β amino acid sequence).
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Binding kinetics of TCRs iNKT, 5E, and 5B 
to the CD1d–𝛂-GalCer complex
Soluble versions of the native TCRs iNKT, 5E, and 5B with 
an engineered disulphide linkage between cysteines intro-
duced at positions 48 and 57 of the TCR Cα and Cβ genes, 
respectively, (henceforth termed disulfi de-linked [ds]TCRs) 
were generated by in vitro refolding of completely denatured 
and reduced TCR α and β chain Escherichia coli inclusion 
body proteins. All three dsTCRs refolded with >20% 
 effi  ciency to produce protein preparations which were 
>95% pure after ion-exchange and gel-fi ltration chroma-
tography, as judged by Coomassie-stained SDS-PAGE analysis 
(unpublished data).
BIAcore surface plasmon resonance analyses of iNKT, 5E, 
and 5B dsTCRs binding to CD1d–α-GalCer complex are 
shown in Fig. 2.[ID]FIG2[/ID] No binding of these dsTCRs to various 
control proteins (see Materials and methods) was  detected. 
Conversely, an HLA-A2*01/NY-ESO-1–specifi c TCR 
(12) failed to bind to CD1d–α-GalCer complex (unpub-
lished data).
The equilibrium dissociation constants (KD), based on 
dsTCR binding to the CD1d–α-GalCer complex at equilib-
rium in a typical experiment, were 6.7, 6.9, and 4.2 μM for 
iNKT, 5E, and 5B, respectively (Fig. 2 A). The slightly lower 
KD for 5B was observed in three separate experiments. Good 
agreement was observed between the affi  nities determined 
kinetically (the ratio of koff  to kon; Fig. 2 B) and those deter-
mined by equilibrium measurements (Fig. 2 A). Kinetic 
binding experiments revealed relatively fast binding kinetics 
to CD1d–α-GalCer for all three dsTCRs, but the three 
 dsTCRs exhibited signifi cant diff erences with regard to their 
koff  and kon. In particular, the half-life of dissociation (t1/2) was 
three times slower for dsTCR 5E (3.3 s) compared to iNKT 
(1.1 s) and 5B (1 s). Since the ability of CD1d–α-GalCer 
monomers to stain iNKT, 5E, and 5B T cell clones is likely 
to be determined by the rate of dissociation rather than the 
affi  nity (koff ), the threefold slower t1/2 measured for the inter-
action of CD1d–α-GalCer monomer with dsTCR 5E com-
pared to 5B could explain the diff erences in monomer 
staining described above. These results demonstrate that 
 human TCR Vα chains other than Vα24 can be used by 
CD1d–α-GalCer–specifi c TCRs, in combination with 
Vβ11, to mediate binding to the CD1d–α-GalCer complex 
that is similar to that of iNKT TCRs. Therefore, the syn-
chronous expansion of iNKT and Vα24− T cells in response 
to α-GalCer in vitro (8) and in vivo (9) could be accounted for 
by a similar binding affi  nity to CD1d–α-GalCer monomers. 
To investigate whether Vα24− and Vα24+ iNKT TCRs dif-
fer with regard to their structural frameworks, and to com-
pare their structure to conventional pMHC-specifi c TCRs, 
we crystallized the three glycolipid-specifi c dsTCRs and deter-
mined their structures.
Structures of the iNKT, 5E, and 5B dsTCRs
The iNKT dsTCR crystallized in space group C2 with 
three molecules in the crystallographic asymmetric unit; 5E 
dsTCR in space group P3221 with a single molecule in the 
asymmetric unit; and 5B dsTCR in space group P3121, also 
with a single molecule in the asymmetric unit. The structures 
of the iNKT, 5E, and 5B dsTCRs were solved by molecular 
replacement and refi ned using data to 3.5, 2.25, and 2.6 Å 
resolution, respectively (Table I).[ID]TBL1[/ID] Composite OMIT maps 
for the α and β chain CDR1 and CDR2 loops in each of 
the three dsTCR structures are illustrated in Fig. S2 (http://
www.jem.org/cgi/content/full/jem.20052369/DC1).
The overall architecture of all three proteins was similar 
(as shown for the iNKT dsTCR; Fig. 3, A and B) with main 
chain conformations typical of previously reported TCR 
structures (Fig. 3, B–D; see following paragraph)[ID]FIG3[/ID]. Also, as 
noted for other TCR structures (13) the constant domain 
of the α chain in the dsTCR structures appeared, with the 
exception of the CDR loops, to be the most fl exible re-
gion (as judged from crystallographic B factors). The three 
copies of the iNKT dsTCR structure were in most respects 
 identical to within experimental error (the second and third 
copies  superimposed onto the fi rst with an root mean square 
 deviation (rmsd) of 0.37 Å and 0.45 Å, respectively for a 
 selected “core set” of Cα atoms; see Materials and methods), 
Figure 2. Binding of human invariant NKT and V 24-independent, 
V 11-positive TCRs to CD1d–𝛂-GalCer. Surface plasmon resonance 
measurements (BiaCore) for binding of the three dsTCRs iNKT, 5B, and 5E 
to immobilized CD1d–α-GalCer complex (control proteins: as described in 
Materials and methods) at equilibrium are shown in A and kinetic mea-
surements are shown in B. (t1/2, dissociation half-life; kon/koff, association/
dissociation rate constants; KD, calculated dissociation constant).
702 HUMAN INKT-TCR STRUCTURE | Gadola et al.
and unless otherwise stated the fi rst copy was taken as the 
representative structure in the following analyses (Fig. 3B).
Structural comparison of human CD1d-glycolipid– and 
CD1d-pMHC–specifi c TCRs
Superposition of our three dsTCRs with previously deter-
mined crystal structures of pMHC-specifi c TCRs resulted in 
rmsd values (based on a “core set” of framework residues; see 
Materials and methods) ranging from 1.1 to 2.0 Å for com-
parisons with human TCRs and 1.5 to 2.1 Å for mouse 
TCRs (Fig. 3 B). These rmsd values were somewhat infl ated 
by diff erences in the relative domain orientations between 
TCRs. Taken in isolation, the CD1d–α-GalCer–specifi c Vα 
domains superimposed with rmsd values of 0.3–1.0 Å with 
each other and 0.5–2.0 Å with those of pMHC-specifi c hu-
man TCRs, whereas the Vβ regions had a rmsd range of 
0.3–0.7 Å compared with each other and 0.8–1.5 Å with 
other human TCRs. These comparisons revealed no system-
atic variations in framework structure that distinguished the 
CD1d–α-GalCer–specifi c human dsTCRs.
The CDR1 and CDR2 loops of the three CD1d–α- 
 GalCer–specifi c TCRs were also comparable to those of the 
pMHC-specifi c TCRs (Fig. 3, C and D). Al-Lazikani et al. 
(14) have grouped the CDR1 and CDR2 loops of TCRs into 
Table I. Statistics for data collection and refi nement
Crystallographic statistics
5E TCR 5B TCR i NKT-TCR
Data collection
 Resolution range (Å)a 30–2.25 18–2.6 30–3.5
 (highest resolution shell) (2.3–2.25) (2.67–2.6) (3.62–3.5)
 Number of collected refl ections 271,030 73,961 75,995
 Unique refl ections 21,795 13,750 23,622
 Completeness (%) 98.8 (89.5) 96.6 (87.4) 98.1 (90.9)
 Rmerge (%)b 7.1 (23.8) 12 (55) 18.3 (88.0)
 I/σI 31 (7.9) 10.4 (2.2) 6.4 (1.4)
 Space group P3221 P3121 C2
 Unit cell dimensions (Å) (a, b, c) 64.5, 64.5, 184.9 64.0, 64.0, 185 289.4, 85.0, 78.9
 Unit cell angles (º) (α, β, γ) 90, 90, 120 90, 90, 120 90, 103, 90
 Source ESRF ID14-EH2 SRS Daresbury 14.2 ESRF ID14-EH1
Model refi nement
 Resolution range (Å) 30–2.25 18–2.6 30–3.5 
 Number of refl ections (test set)c 20,555 (1,098) 13,033 (656) 23,453 (1,193)
 Rcryst (%)d 18.8 21.7 28.3
 Rfree (%)e 26.8 31.8 35.0
 Number of nonhydrogen protein atoms 3,436 3,392 10,330
 Number of water molecules 286 61 0
 Average B factors
  Protein (Å2) 34.4 39.6 46.1
  Water (Å2) 30.2 23.5 n/a
 r.m.s. deviation from ideality
  Bond lengths (Å) 0.012 0.009 0.006
  Bond angles (º) 1.41 1.32 1.20
 r.m.s. deviation B factors (bonded atoms)
  Main chain (Å2) 2.3 1.8 2.4
  Side chain (Å2) 3.1 1.9 4.6
 Ramachandran plot
  Favored (%) 90.4 83.3 78.8
  Allowed (%) 8.3 15.4 19.0
  Generous (%) 1.0 0.3 1.7
  Unfavored (%) 0.3 1.0 0.5
aValues in parentheses refer to the highest resolution shell of data.
bRmerge = ΣhΣi | Ii(hkl) − <I(hkl)> I / ΣhΣiIi(hkl), where Ii(hkl) is the “ith” measurement of refl ection hkl and <I(hkl)> is the weighted mean of all measurements of 
refl ection hkl.
cTest set is a randomly chosen set of refl ections omitted from the refi nement process.
dRcryst = Σh || Fobs(hkl)| − | Fcalc(hkl)|| / Σh|Fobs(hkl)|, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively.
eRfree is equivalent to Rcryst but calculated for the test set of refl ections.
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sets of canonical structures based on loop length and the con-
servation of certain key residues. Our analysis of the CDR 
loops of the three CD1d–α-GalCer–specifi c TCR structures 
demonstrated that they conform to these canonical structures.
CDR loop architecture
CDR loop architectures for the iNKT, 5E, and 5B dsTCRs 
are displayed in Fig. 4.[ID]FIG4[/ID] The CDR1α loop of the dsTCR 
iNKT corresponds most closely to the α1-2 canonical struc-
ture of Al-Lazikani et al. (14). In contrast, the CDR1α loops 
of dsTCRs 5E and 5B both have α1-1–type canonical struc-
tures; in 5E the Ser26-Oγ forms a hydrogen bond to the 
backbone nitrogen of Ser28 and packs against the edge of the 
Phe30 aromatic ring, whereas in 5B the edge of the Tyr26 
ring packs against the aliphatic side chains of Ile30 and Leu33 
(Fig. 4 A and Fig. S2). The iNKT TCR CDR2α loop has a 
α2-2 canonical structure as does the CDR2α loop in dsTCR 
5B. Conversely, the CDR2α loop of TCR 5E adopts a type 
II turn conformation, which is characteristic of the α2-4 
 canonical structure, with a main chain hydrogen bond 
 between the carbonyl oxygen of Thr52 and the nitrogen of 
Glu54 (Fig. 4 B and Fig. S2). Thus, CD1d–α-GalCer– specifi c 
TCRs can show substantial diff erences in the structures of 
their CDR1α and CDR2α loops but none deviate from 
standard TCR architectures.
In contrast to the variation in their α chains, all three 
CD1d–α-GalCer–specifi c TCRs used Vβ11 and their 
CDR1β and CDR2β loops share identical main chain con-
formations. The CDR1β loop is a β1-1 canonical structure, 
with Oε1 and Nε2 of Gln26 forming hydrogen bonds with the 
main chain nitrogen of Met28 and carbonyl oxygen of His30, 
respectively. The CDR2β loop is a β2-1 canonical struc-
ture, with the carbonyl oxygen of Ser50 forming hydrogen
bonds to the main chain of nitrogen of Gly52 (Fig. 4, C
and D and Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20052369/DC1).
No canonical structures have been described for the much 
more diverse CDR3 loops. The sequences of the CDR3α 
loops for TCRs iNKT, 5E, and 5B diff er only for residues 
91–93 (which neighbor the disulfi de bond forming Cys90 of 
the conserved TCR framework). These sequence diff erences 
are therefore located in a part of the CDR3α loop which is 
unlikely to be directly involved in binding to the CD1d–α-
GalCer complex. However, these sequence diff erences, com-
bined with diff erences in the environment, which the 
CDR3α loops experience within the iNKT, 5E, and 5B 
dsTCR crystals, result in substantially diff erent main chain 
conformations. Within this range of conformations, the 
CDR3α loop structures of TCRs 5E and iNKT are more 
similar to each other, compared to TCR 5B. This may, at 
least in part, refl ect in the sequence of 5B, where residues 92 
and 93 are a proline residue and a bulky phenylalanine, re-
spectively, whereas small residues occupy these positions in 
iNKT and 5E. However, the conformational variations are 
also in line with the fl exibility characteristic of many αβTCR 
CDR3 loops (for review see references 13, 15).
In contrast to the conservation seen for the CDR1β and 
CDR2β loops, the CDR3β loop sequences and hence struc-
tures are diff erent for each of the three CD1d–α-GalCer–
specifi c TCRs. The CDR3β loop of the iNKT dsTCR 
Figure 3. Overall structure of the three TCRs and comparison with 
the canonical MHC binding TCR structures. (A) Ribbon plot of the 
iNKT-TCR structure with α-chain shown in red and β-chain in blue. The 
constant domains are at the top and the variable domains at the bottom 
of the panel. CDR loops are color coded: CDR1α (green), CDR2α (orange), 
CDR3α (dark blue), CDR3β (light blue), CDR2β (yellow), and CDR1β 
 (magenta). (B) Superposition of the Cα traces of the dsTCRs: iNKT, fi rst 
molecule in the asymmetric unit (green), second (red), and third (gray), 
5E (yellow), and 5B (blue). Orientation is the same as for A. (C) Close-up 
view of the hypervariable loop structures from all published canonical 
MHC class I–binding TCRs and the three CD1d–α−GalCer–specifi c dsTCR 
α chains (left two fi gures) and β chains (right two fi gures), each seen 
from the side (top) and top (bottom). 5E dsTCR is shown in yellow, 5B 
dsTCR in blue, iNKT dsTCR in green, and the other TCR chains are shown in 
the following colors: 1A07, orange; 1BD2, dark green; 2BNQ, indigo; 1LP9, 
red; 1MI5, pink; 1OGA, cyan; 1KGC, mid-grey; and 2BNU, slate blue. The 
mouse MHC class I binding TCR 2CKB, which we used for our docking of 
the iNKT dsTCR, onto hCD1d is depicted in thick brown lines. (D) The same 
presentation as in C shown only for the three dsTCR structures: iNKT in 
green, 5E in yellow, and 5B in blue.
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structure adopts an extended conformation, with main chain 
hydrogen bonds between the Gly99 nitrogen and the Ala101 
carbonyl oxygen as well as between the Glu96 nitrogen and 
the Tyr102 carbonyl oxygen. The TCR 5E also has an ex-
tended CDR3β loop, again with several main-chain hydro-
gen bonds stabilizing this conformation. In the structure of 
TCR 5B, the CDR3β loop is less extended with more inter-
actions between side chains than in TCR 5E.
Overall, the CD1d–α-GalCer recognition surfaces 
(formed by the CDR loops) of dsTCRs 5E and iNKT are 
quite similar, whereas dsTCR 5B has more positively charged 
residues on its surface (Fig. S5, available at http://www.jem.
org/cgi/content/full/jem.20052369/DC1).
A model for CD1d recognition
Our analysis showing that the CDR loops of CD1d–α-
 GalCer–specifi c dsTCR structures resemble those of pMHC-
specifi c TCRs supports the idea that the mode of binding 
of TCRs to CD1d–lipid and CD1d–pMHC complexes is 
similar. The current data base of TCR-pMHC crystal struc-
tures in general shows the TCR CDR1 and 2 loops making 
contact with the α1 and α2 helices of the antigen binding site 
and the CDR3 loops making the most intimate contact with 
the antigen (for review see references 13, 15); however, the 
orientation, and position, of the TCR relative to the pMHC 
antigen binding groove can vary signifi cantly between com-
plexes. Thus, we may expect that docking models for TCRs 
to CD1d–α-GalCer may provide some useful general in-
sights but will not reliably predict the detailed interaction 
interface. To generate such models, we selected as a template 
for the relative TCR to antigen binding groove orientation a 
pMHC-TCR crystal structure which minimized steric clashes
between the TCRs and CD1d–α-GalCer (see Materials 
and methods).
Docking models (Fig. 5, A–C) were generated for the 
iNKT, 5B, and 5E TCR crystal structures described above 
and the previously reported crystal structure of human 
CD1d–α-GalCer (PDB code 1ZT4) (16).[ID]FIG5[/ID] In all three mod-
els, the CDR1 and CDR2 loops of the TCR Vα and Vβ 
main chains make sterically acceptable contacts with the 
CD1d–α-GalCer molecule. The CDR1α loops are predicted 
to contact the CD1d surface in the region of α1 helix resi-
dues 61–69 and the CDR2α loops in the region of α2 helix 
residues 156–160. The interactions of the CDR2β loop are 
particularly noteworthy. Arg79 points, fi nger-like, from the 
CD1d α1 helix (Fig. S4) into a shallow groove, formed by 
the CDR2β loop and present in all three TCRs (Fig. 5 D). 
This conserved surface is formed by a set of polar and charged 
residues (Tyr49, Tyr51, Ser55, and Glu57), which could 
 mediate electrostatically favorable interactions with Arg79. 
Arg79 is conserved between mouse and human CD1d (17, 
18); however, comparison with the three currently available 
mouse CD1d structures (19–21) (accession nos. 1CD1 , 1Z5L , 
and 1ZHN ) indices that, certainly before TCR binding, this 
residue is conformationally very fl exible (Fig. S4).
Our models suggest that the TCR CDR3α and CDR3β 
loops plus the CDR1β loop are responsible for making inter-
actions with ligands presented by CD1d. Notably, the posi-
tively charged Lys32 side chain in the CDR1β loop appears 
to be a good candidate for mediating specifi c recognition of 
the carbohydrate head group of α-GalCer (Fig. 5 E). Pre-
vious studies have suggested that CD1/glycolipid-specifi c 
TCRs bind CD1 in a manner similar to that predicted by our 
docking models such that the CDR3 loops are positioned 
centrally over the polar head group of the glycolipid ligand 
(22–25) (Fig. S5). All three dsTCR crystal structures exhibit 
a large surface cavity between the CDR3 loops of the α and 
β chains (Fig. S5), which could potentially, with some con-
formational changes of the CDR3 loops, clamp around the 
sugar head group of the antigen α-GalCer. Such conforma-
tional fl exibility would be consistent with the diff erences in 
conformation observed between the CDR3α loops in our three 
unliganded TCR structures. Certainly some conformational 
Figure 4. Architectures of CD1d–𝛂−GalCer–specifi c TCR CDR1 
and CDR2 loops. The loop architectures are shown for the CDR1α (A), 
the CDR2α (B), the CDR1β (C), and the CDR2β loops (D) of the three 
dsTCR structures iNKT (left), 5E (middle), and 5B (right). Carbon atoms are 
depicted in yellow.
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changes in the CDR3α and CDR3β loops of the three 
CD1d–α-GalCer–specifi c TCRs are predicted by the cur-
rent docking studies since in all three model complexes these 
loops (in their unliganded conformations) made signifi cant 
steric clashes with the CD1d–α-GalCer.
D I S C U S S I O N 
The highly conserved CD1d-restricted iNKT cells are be-
lieved to bridge innate and adaptive immune responses by 
exerting potent immune regulatory functions (1). A key 
question of iNKT biology is how their TCRs recognize 
CD1d-presented glycolipid ligands. Remarkably, human and 
mouse iNKT use the homologous Vα24/Jα18 and Vα14/
Jα18 gene families, respectively, for TCRs that also share 
 almost identical amino acid sequences in their CDR3α loops 
(3, 4). On the other hand, diverse TCRs from autoreactive 
and nonlipid-specifi c CD1d-restricted hybridomas can rec-
ognize CD1d proteins (5, 6). It has therefore been proposed 
that human and mouse iNKT recognize the same or at least 
a very similar CD1d-bound ligand via their invariant CDR3α 
loop. In support of this hypothesis, it has been previously 
shown that discrete diff erences in the carbohydrate moiety of 
the CD1d ligand steer recognition by iNKT TCRs (7).
Here we provide further evidence for direct recognition 
of CD1d-bound ligands by the CDR3α loop. First, the high 
degree of conservation of CDR3α peptide sequences be-
tween iNKT clones and diff erent native CD1d–α-GalCer–
specifi c Vα24−/Vβ11+ clones argues strongly for the 
CDR3α loop having a key role in ligand recognition. Second, 
N-region modifi cations used by the two Vα24-independent 
T cell clones clearly indicate their antigen-driven selection. 
Conversely, our fi ndings demonstrate that Vα24 gene seg-
ments are not essential for CD1d–α-GalCer recognition. 
Consistent with these observations, BiaCore analysis showed 
that human invariant Vα24+ TCR and Vα24− independent 
Vβ11+ TCRs have similar binding affi  nities to CD1d–α-
GalCer monomers. These results raise the question as to 
whether the dominant usage of Vα24 TCR chains by iNKT 
TCRs is actually due to favorable binding to CD1d mole-
cules loaded with the natural ligand(s) or to other factors. 
 Although we cannot rule out the former possibility, it is pos-
sible that the observed dominance of Vα24 gene segments 
over other Vα gene segments in human CD1d–α-GalCer–
recognizing T lymphocytes in vivo could be due to early 
 terminal deoxynucleotidyltransferase–independent rearrange-
ment of Vα24-Jα18 segments, as is the case for the invariant 
TCR gamma and delta chains of murine DECs (26). Con-
sistent with this hypothesis mice lacking terminal deoxyn-
ucleotidyltransferase are still capable of generating CD1d–α-
GalCer–recognizing T lymphocytes (27).
Figure 5. Docking of the TCRs onto CD1d, based on the TCR 
2C–pMHC complex. (A) Ribbon plot of the modeled iNKT dsTCR–CD1d 
complex structure with CD1d shown in cyan and iNKT in gold. For the 
interface, the α-GalCer molecule is shown in orange and the CDR loops 
are depicted in the color coding of Fig. 2 A. (B) Structural alignment of 
the modeled TCR–CD1d complexes (iNKT: fi rst molecule in the asymmetric 
unit [green], 5E [yellow], and 5B [blue]. The CD1d molecule is shown in 
cyan, α-GalCer in orange. The Cα-trace for the TCR 2C-pMHC H2K (PDB 
entry: 2CKB) complex is shown as thick brown lines. (C) Close-up view of 
the iNKT CD1d interface from A focused on the CDR loops. For better 
visualization, the orientation is rotated from that in A by 180° around the 
y axis. (D and E) Close-up views of the model complex centered on the 
CDR1β (D) and 2β (E) loops of the three dsTCRs, depicted in the same 
colors as in B. Side chains are shown for residues which the model impli-
cates in TCR–CD1d–α-GalCer binding. For D, the molecular surface of the 
iNKT-TCR is shown, with Arg79 from CD1d fi tting into a surface depres-
sion (in the crystal structure of the unliganded CD1d this side chain is 
fl exible and has here been slightly rebuilt).
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Although our measurements are within the range of KDs 
measured for human and mouse class I– and class II–restricted 
TCR (28), previous BiaCore studies with mouse NKT TCR 
have reported considerably higher binding affi  nities to mouse 
CD1d–α-GalCer monomers, with KD values ranging from 
0.098 to 0.35 μM (29–31). Our studies do not highlight any 
structural characteristics that could explain the diff erence in 
affi  nities between mouse and human iNKT TCR. One of 
several possible explanations could be the diff erent nature of 
the recombinant TCRs used in the two studies, i.e., single-
chain mouse TCRs (previous studies) versus ds human TCRs 
(this study).
A direct role for the CDR3α loops in peptide specifi city 
of pMHC-restricted TCRs was originally confi rmed in ex-
periments with transgenic mice, where fi xation of both a re-
arranged Vβ chain and the peptide antigen resulted in 
selection of only one Vα chain (32). Likewise, a fi xed Vα 
chain and peptide antigen resulted in selection of diff erent 
but restricted Vβ chains (32). Crystal structures of peptide-
specifi c TCRs in complex with their pMHC ligands have 
revealed that the TCRs bind in a relatively conserved diago-
nal orientation, thereby positioning their CDR3α and 
CDR3β loops over the peptide-containing antigen-binding 
groove (33, 34). The structural similarity of MHC class I and 
CD1d molecules (16, 19), plus the high degree of structural 
conservation between our three CD1d-specifi c TCRs and 
pMHC-specifi c TCRs, is suggestive of similar mechanisms 
for TCR/MHC and TCR/CD1d recognition. We therefore 
generated a TCR–CD1d docking model based on the avail-
able database of crystal structures for TCR/MHC class I 
complexes. Our analysis of the functional and structural data 
for CD1d–α-GalCer and cognate TCRs in the context of 
the TCR–CD1d docking model provides several highly 
plausible insights into details of the TCR–CD1d interaction. 
Consistent with previous modeling exercises for TCR–CD1 
binding (22–25) the current model predicts that all three 
CD1d–α-GalCer–specifi c TCRs position their CDR3α and 
CDR3β loops in close proximity to the carbohydrate head 
group of the CD1d-bound α-GalCer. In addition, as seen in 
TCR-pMHC recognition systems (34) the model also im-
plies that the CDR3 loops must undergo conformational 
changes between the unliganded and CD1d-liganded states. 
Such changes are potentially important in allowing TCR 
recognition of other CD1d-presented antigens (such as iso-
globoside or phosphatidylinositol mannoside) (35, 36). Given 
the inaccuracy of the docking model, we cannot comment in 
detail on these TCR–ligand interactions. However, the 
model does provide new insights into the potential contribu-
tion of the CDR1 and CDR2 loops to CD1d binding.
The peptide sequences of the CDR1α and CDR2α loops 
are not conserved between our three CD1d-recognizing 
TCRs although these TCRs exhibit almost identical avidity 
for CD1d–α-GalCer. Moreover, human Vα24 and mouse 
Vα14 germline CDR1α and CDR2α sequences are not simi-
lar, nor are the CD1d residues conserved between human and 
mouse at the contact sites predicted by our docking models. 
Thus, the CDR1α and the CDR2α loops may either not be 
important in stabilization of TCR–CD1d binding, or may 
make their contribution to binding by several equally viable 
alternatives (depending on germline CDR1α and CDR2α 
sequence) which involve no conserved interactions.
In contrast, based on the observation that randomly cho-
sen Vβ8.2 chains can confer strong affi  nity to mouse Vα14-
Jα18 TCR (31), and the fact that CDR3β loops used by 
iNKT are highly polymorphic (27), it has been suggested 
that CDR1β and/or CDR2β, rather than CDR3β, may be 
 important for steering iNKT TCR avidity. The model 
 presented here revealed a surprisingly good docking of 
the CDR2β loop onto the CD1d protein surface. Two of 
the CD1d residues involved in this putative interface, Arg79 
and Asp80, have previously been predicted to be critically 
involved in TCR binding on the basis of site-directed mu-
tagenesis studies (24, 29). Moreover, alignment of the hu-
man Vβ11 gene with the related mouse Vβ8.2 gene revealed 
89% identity of their CDR2β sequences, whereas the over-
all identity of these two Vβ amino acid sequences was only 
54% (Fig. 6).[ID]FIG6[/ID] Furthermore, all fi ve CD1d residues contacted 
by CDR2β in our model are conserved between the other-
wise only 66% identical human and mouse CD1d protein 
 sequences. Although human iNKT TCRs exclusively use 
Figure 6. CD1d-contacting residues are conserved within CDR2 
loops of dominant human and mouse iNKT TCR V chains. Alignments 
are shown of the CDR1β and CDR2β regions of the human TCR Vβ11 chain 
with different TCR β chains of mouse iNKT TCRs are shown. Amino acids 
predicted by the docking model to directly contact CD1d by the docking 
model are marked by “+” above the sequence. An asterisk “*” under the 
sequence symbolizes identical residues; conserved amino acid substitu-
tions are denoted by “:” and semiconserved substitutions by “.”. 
(Alignments were carried out using ClustalW sequence alignment. 
http://www.ebi.ac.uk/clustalw/).
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Vβ11, mouse iNKT can use other Vβ chains in addition to 
the predominantly used Vβ8.1 and Vβ8.2 chains (37). 
 Recent evidence has indicated that the dominant use of cer-
tain Vβ chains by mouse iNKT is directly related to the Vβ 
chain’s contribution to TCR avidity (38, 39). In particular, 
Vβ8.2 chains have been demonstrated to confer higher 
TCR avidity to Vα14-Jα18 iNKT compared to the sub-
dominant Vβ7 chains (39). Interestingly, comparison of the 
complete  human Vβ11 CDR2β sequence as well as of the 
fi ve predicted CD1d-contacting CDR2β residues with 
the diff erent mouse iNKT-associated Vβ chains showed 
that mouse Vβ8.2 was most similar to human Vβ11, fol-
lowed in order by Vβ8.1, Vβ7, and Vβ8.3. Together these 
facts demonstrate a close link between the CDR2β loop 
structure and the dominant use of Vβ11 and Vβ8.2/Vβ8.1 
chains by human and mouse iNKT, respectively. Similar 
structural principles have been shown to govern Vβ chain 
usage by certain immunodominant pMHC-specifi c TCRs 
such as human HLA-A2*01–  restricted, infl uenza matrix 
protein–specifi c TCRs (40).
Comparison of the human CD1d–α-GalCer crystal struc-
tures (16) with the recently solved structure of mouse CD1d 
loaded with the self-ligand phosphatidylcholine (PC) (21) 
shows important diff erences in the positioning of the anti-
genic headgroup, which are caused by both inherent diff er-
ences of anomeric headgroup conformation as well as 
interactions of the headgroup with CD1d protein. In contrast 
to the galactose of α-GalCer, the phosphate of the PC head-
group makes a charge interaction with Arg79 of the α2-helix. 
The authors suggest a model for iNKT–TCR interactions 
with CD1d–antigen complexes based on a comparison of sur-
face clefts which provide suitable docking sites for TCR CDR 
loops in MHC peptide and CD1d–antigen structures. From 
this analysis, the PC headgroup was predicted to be contacted 
by CDR3β and CDR1 (21). These predictions are fully con-
sistent with our docking model for iNKT TCR–CD1d–anti-
gen binding under the assumption that diff erent parts of the 
iNKT TCR (i.e., diff erent CDR loops) are involved in rec-
ognizing either agonistic (α-GalCer) or nonagonistic (PC) 
CD1d–antigens. We hypothesize that agonistic binding of 
iNKT TCRs to CD1d–antigen molecules requires two con-
ditions, namely recognition of the CD1d–antigen complex by 
CDR3α as well as stable docking of the CDR2β loop onto 
the α2 helix of CD1d, involving a charge interaction between 
Glu57 (iNKT TCR) with Arg79 (CD1d). Neither condition 
would be fulfi lled in the case of PC-loaded CD1d proteins.
In conclusion, this study demonstrates that human CD1d–α-
GalCer–specifi c TCRs are structurally indistinguishable from 
pMHC-specifi c TCRs and supports the hypothesis that they 
bind the CD1d molecule in a similar diagonal orientation to 
that of pMHC-recognizing TCRs. Our data provide compel-
ling evidence that the CDR3 loop of the invariant Vα chain is 
essential for recognition of the carbohydrate head group of the 
CD1d ligand, and suggest that the CDR2 loop of the Vβ11 
chain is strongly involved in binding to the CD1d protein.
MATERIALS AND METHODS
Generation of V𝛂24+ and V𝛂24−, CD1d–𝛂-GalCer–specifi c T cell 
clones. Invariant Vα24+/Vβ11+NKT cells were expanded in vitro by 
stimulation of human peripheral blood mononuclear cells with 100 nM 
α-GalCer. After 14 d, single CD4−/CD8− (DN) iNKT cells were sorted 
into round bottom 96-well plates using a FACSVantage cell sorter and re-
stimulated with irradiated allogenic feeder cells and 100 nM α-GalCer. The 
Vα24-negative, CD1d–α-GalCer–specifi c T cell line 5.Y was derived from 
a buff y coat stimulated with 100 nM α-GalCer in the presence of irradi-
ated allogenic human PBMC. FACSVantage-assisted cloning of Vα24−/
CD1d–α-GalCer tetramer+ T cells was carried out as described above for 
the iNKT cell cloning. All T cell clones were maintained in Iscove’s modi-
fi ed Dulbecco’s minimum essential medium (Sigma-Aldrich) supplemented 
with 5% heat-inactivated human serum, 1% streptomycin/penicillamine, 
and 1% glutamine.
Flow cytometry. 4 wk after restimulation, T lymphocyte clones (1 × 105 
cells per staining) were analyzed for purity and viability by FACS using 
propidium iodide (Sigma-Aldrich), FITC–anti-Vα24 and RPE–anti-Vβ11 
(Serotec), as well as Streptavidin-APC–conjugated CD1d–α-GalCer tetra-
mers (41) in combination with FITC–anti-CD3, PerCP–anti-CD4, and 
RPE–anti-CD8β antibodies (all from BD Pharmingen). All 14 isolated 
Vα24−, CD1d–α-GalCer tetramer+ T cell clones were also analyzed by 
CD1d–α-GalCer monomer staining as described (8). In brief, cells were in-
cubated with biotinylated CD1d–α-GalCer monomers on ice for 30 min, 
washed twice with ice-cold PBS, stained with R-PE-Extraavidin (Sigma-
Aldrich) on ice for 30 minutes, and washed again twice with ice-cold PBS. 
All samples were analyzed on a FACSCalibur fl ow cytometer, and data were 
processed using CellQuest software (BD Biosciences).
Preparation of soluble biotinylated CD1d–𝛂-GalCer complexes and 
CD1d–𝛂-GalCer tetramers. Human biotinlyated CD1d–α-GalCer com-
plexes and Streptavidin-linked CD1d–α-GalCer tetramers were prepared by 
in vitro refolding from bacterially expressed inclusion bodies and synthetic 
α-GalCer as previously described (41).
Manufacture of soluble heterodimeric TCRs. The generation of solu-
ble TCR heterodimers was based on the procedure described by Boulter et 
al. (42). The extracellular region of each TCR chain was individually cloned in 
the bacterial expression vector pGMT7 and expressed in E. coli BL21-DE3
(pLysS). Residues Thr48 and Ser57, respectively, of the α- and β-chain 
TCR constant region domains were both mutated to cysteine. Expression, 
refolding, and purifi cation of the resultant dsTCR heterodimers was carried 
out as described previously (43).
Surface plasmon resonance. Approximately 5,000 response units of 
streptavidin were linked to a BIAcore CM-5 chip (BIAcore AB) using 
the amino-coupling kit according to manufacturer’s instructions, and 
CD1d–α-GalCer complexes or control proteins (CD1b–β-galactosylce-
ramide complex, CD1d–ganglioside GM1, and HLA-A2*01-NY-Eso-
1(157-165) complex) were fl owed over individual fl ow cells at a 
concentration of 50 μg/ml until the response measured 1,000 
 response units. Serial dilutions of 5E, 5B, and iNKT dsTCRs (and for 
some control experiments a HLA-A2*01-NY-Eso-1–specifi c dsTCR) 
were then fl owed over the relevant fl ow cells at a rate of 5 μl/min (for 
equilibrium binding measurements) or 50 μl/min (for kinetic measure-
ments). Responses were recorded in real time on a Biacore 3000 machine 
at 25°C, and data were analyzed using BIAevaluation software (BIAcore). 
Equilibrium dissociation constants (KD values) were determined assuming 
a 1:1 interaction (A + B ↔ AB) by plotting specifi c equilibrium binding 
responses against protein concentrations followed by nonlinear least 
squares fi tting of the Langmuir binding equation, AB = B × ABmax/(KD 
+ B), and were confi rmed by linear Scatchard plot analysis using Origin 
6.0 software (Microcal). Kinetic binding parameters (kon and koff ) were 
determined using BIAevaluation software.
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Crystallization of TCRs 5E, 5B, and iNKT. 5E, 5B, and iNKT dsT-
CRs were concentrated to 10 mg/ml in buff er (100 mM NaCl, 10 mM Tris, 
pH 8.0) and crystallized by the sitting drop vapor diff usion method. The 
crystallizations of 5E and 5B dsTCRs were set up as nanoliter scale drops 
(100 nL of protein plus 100 nL of reservoir solution) using a Cartesian Tech-
nologies Microsys MIC4000 (Genomic Technologies) (44). Crystallizations 
of the iNKT dsTCR were set up using 2 μL plus 2 μL drops hand pipetted 
into microbridges.
Crystals of 5E dsTCR grew at room temperature in 200 mM magne-
sium sulphate and 20% polyethylene glycol 3350. 5B dsTCR crystals grew 
at room temperature at a fi nal concentration of 10 mg ml−1 in 200 mM 
di-ammonium tartrate, 20% polyethylene glycol 3350. iNKT dsTCR crys-
tals grew at room temperature at a fi nal concentration of 10 mg ml−1 in 
0.5 M NaCl, 11% polyethylene glycol 8000, 50 mM HEPES, pH 7.0. Crystals 
were soaked briefl y in per-fl uoropolyether oil (PFPE) before being fl ash 
cooled and maintained at 100 K in a cryostream.
Diff raction data for the 5E dsTCR were recorded at station ID14-EH2 
of the European Synchrotron Radiation Facility (ESRF) with an ADSC Q4 
CCD detector. Because of detector overloads at low crystal to detector dis-
tance both a high-resolution (175 mm detector distance) and a low-resolu-
tion (300 mm detector distance) dataset were collected from the same crystal. 
The crystal belonged to the spacegroup P3221 (a = b = 64.5 Å, c = 184.9 Å) 
and both datasets were autoindexed with DENZO and scaled together using 
SCALEPACK (http://www.hkl-xray.com) (Table I). There was a single 
molecule in the asymmetric unit and 44% solvent.
Data for the 5B dsTCR were recorded at station 14.2 of the Synchro-
tron Radiation Source at the Daresbury Laboratory (SRS) with an ADSC 
Q4 CCD detector. The crystal belonged to the spacegroup P3121 (a = b = 
64.0 Å, c = 185.0 Å), with a single molecule in the asymmetric unit and 43% 
solvent. The diff raction from this crystal gave smeared spots, which required 
use of a large spot size in DENZO to ensure that the full spot intensities were 
integrated, and these were then scaled using SCALEPACK (Table I).
That the 5E and 5B dsTCR crystals have almost identical unit cell pa-
rameters, yet molecular replacement solutions indicated that they had diff er-
ent space groups related by opposite handed screw axes was surprising. 
However, all attempts at reindexing to allow the two data sets to be scaled 
together gave very high χ2 and Rmerge values, clearly indicating that they be-
longed to diff erent space groups.
Data were collected for the iNKT TCR at station ID14-EH1 of the 
ESRF using an ADSC Q4R CCD detector. The crystal belonged to the 
spacegroup C2 (a = 289.4 Å, b = 85.0 Å, c = 78.9 Å, β = 103.9 º), with 
three molecules in the asymmetric unit and 60% solvent. Due to variance 
in the x-ray beam intensity data, processing statistics were poorer than 
expected when the data were indexed and integrated with DENZO and 
SCALEPACK (Table I).
Structure determination and refi nement. Both the Crystallography and 
NMR system (CNS) (45) (http://cns.csb.yale.edu/) and REFMAC CCP4 
(46) (http://www.ccp4.ac.uk) suite of programs were used for refi nement. 
Approximately 5% of refl ections were set aside for the Rfree calculations. See 
Table I for refi nement statistics.
The structure of the 5E dsTCR was determined by molecular replace-
ment using the JM22 TCR structure (40) (PDB-entry 1OGA) as the search 
model in the molecular replacement module of CNS (45). A single strong 
rotation function peak was found and used in a translation search, two 
 symmetry-related peaks in the space group P3221 were found with a high 
correlation coeffi  cient and good packing scores. The top scoring solution 
from this stage was used in subsequent refi nement. After initial rigid-body 
refi nement of the Vα, Vβ, Cα, and Cβ domains using CNS, the sequence 
of JM22 was replaced by the dsTCR 5E sequence, the model rebuilt into 
Fo-Fc and 2Fo-Fc electron density and initially refi ned by simulated anneal-
ing using CNS. As the quality of the model improved, refi nement used 
positional refi nement, individual B-factor refi nement with bulk solvent 
scaling and overall anisotropic B-factor scaling interspersed with manual 
rebuilding using COOT (http://www.ysbl.york.ac.uk/~emsley/coot/) 
(47) and O (http://www.bioxray.dk/~mok/o-fi les.html). In the fi nal 
stages, water molecules were added using ARP-wARP (48) on the basis of 
peaks of at least 3σ in the Fo-Fc electron density maps. The CDR3 loops 
had weak electron density in the 2Fo-Fc maps and were rebuilt from simu-
lated annealing omit maps calculated using CNS with the CDR loops 
omitted from the map calculation. This gave clear density for the path of 
both the CDR3 α and β loops. To complete refi nement, the model was 
subjected to translation libration screw (TLS) and restrained refi nement us-
ing REFMAC (49, 50) with the Vα, Vβ, Cα, and Cβ domains defi ning 
the TLS groups. The fi nal refi ned structure had good stereochemistry, as 
assessed by the program PROCHECK (49; Table I), an Rwork of 18.8% 
(Rfree 26.8%) and comprised residues 3–193 of the α chain, 2–245 of the β 
chain, and 286 water molecules.
The structure of the 5B dsTCR was determined by molecular replace-
ment using the 5E dsTCR structure as the search model in CNS (45). A sin-
gle strong rotation function peak was used in a translation search. One 
unique peak was found in space group P3121 with a high correlation coeffi  -
cient and good packing. After initial rigid-body refi nement of the model 
Vα, Vβ, Cα, and Cβ domains using CNS, the sequence of 5E TCR was re-
placed with that of 5B TCR guided by Fo-Fc and 2Fo-Fc electron density 
maps calculated with CNS. This modeling was followed by refi nement as 
described for 5E dsTCR. The fi nal refi ned structure had good stereochem-
istry, as assessed by the program PROCHECK (49; Table I), an Rwork of 
21.7% (Rfree 31.8%) and comprised residues 10–193 of the α chain, 3–246 of 
the β chain, and 61 water molecules. The high Rfree value and large diff er-
ence from the Rwork seen for this structure is not uncommon for TCR struc-
tures (unpublished data) and may in part be a consequence of the low 
completeness of the data, only 87% in the highest resolution shell (2.67–2.60 A), 
used for refi nement.
The structure of the iNKT dsTCR was solved by molecular replace-
ment using the structure of 1MI5 as the input model for the CaspR web 
interface (http://igs-server.cnrs-mrs.fr/Caspr/index.cgi/). This gave three 
clearly defi ned solutions for the three molecules in the asymmetric unit. 
noncrystallographic symmetry (NCS) restraints were set up for the three 
molecules within the asymmetric unit, but to improve the statistic data SHP 
(Structure Homology Program) (51) was then used to superimpose the 
domains from the fi nal refi ned 5E dsTCR onto the three iNKT dsTCR 
molecules in the asymmetric unit. CNS was then used to carry out rigid 
body refi nement on the twelve domains (Vα, Cα, Vβ, and Cβ for each of 
the three NCS-related molecules), with low restraints placed on the CDR 
loops. Omitting the CDR loops of the molecule, 2Fo-Fc and Fo-Fc elec-
tron density maps were calculated with CNS, and the sequence of the 5E 
dsTCR was replaced with sequence of the dsTCR iNKT in O. Simulated 
annealing refi nement was cycled with manual rebuilding of the molecule 
guided by 2Fo-Fc and Fo-Fc electron density maps in O. The CDR loops 
were built into the resulting electron density from simulated annealing omit 
maps, initially as polyalanine chains, and as the side-chains became apparent 
in subsequent cycles of refi nement these were replaced with the correct se-
quence. The stereochemistry of the model was corrected using Calpha (52). 
Positional and individual B-factor refi nement was carried out with CNS 
using NCS restraints (again with low restraints placed on the CDR loops) 
in later stages of refi nement. The fi nal refi ned structure had good stereo-
chemistry, as assessed by the program PROCHECK (49; Table I), an Rwork 
of 28.3% (Rfree 35.0%) and for each of the three receptors in the asymmetric 
unit comprised residues 2–193 of the α chain, 2–245 of the β chain, and no 
water molecules.
Structural analysis and modeling. Structures of six unique human 
pMHC class I–restricted αβ TCRs have been reported previously, all of 
which were solved as complexes with pMHC class I (accession nos.: 1AO7 , 
1BD2 , 2BNQ , 1LP9 , 1MI5 , and 1OGA ) two of which have also been 
deposited as TCR structures alone (accession nos.: 1KGC is part of 1MI5 
and 2BNU  is part of 2BNQ ). There are currently fi ve unique mouse αβ 
TCR structures in the PDB, four of them are complexes with pMHC class I
(accession nos.: 2CKB , 1FO0 , 1KJ2 , and 1NAM ), three more are TCR 
JEM VOL. 203, March 20, 2006 709
ARTICLE
structures alone ( 1TCR , 1NFD , and 1KB5 ), of these 1TCR and 1KB5 are 
also the TCR part in 2CKB and 1KJ2, respectively. TCR N15 has only 
been solved as complex with hamster Fab (1NFD). Superpositions to ob-
tain the rmsd values between TCR structures were done with the program 
IMPOSE (unpublished program; Esnouf, R., personal communication). A 
“core set” of framework residues were chosen: residues 4–24, 35–47, 71–93, 
and 104–111 of the α chain and residues 5–25, 35–47, 72–96, and 106–114 
of the β chain (residue numbering as in iNKT-TCR) for superpositions 
of the dsTCRs as well as of the human TCRs. This selection was slightly 
changed in the β chain for superpositions of the mouse TCRs, here residues 
72–83 and 88–96 (86–96 in those cases residues 88 and 89 were missing) 
were selected instead of residues 72–96.
Previous eff orts to generate models for TCR–CD1 glycolipid complexes 
(by substituting CD1-glycolipid structures into the position of pMHC in 
TCR–pMHC complexes) resulted in signifi cant steric clashes between the 
CD1 molecule and the TCR (53). However, within the observed range of 
diagonal orientations seen for the TCR interaction footprint on the pMHC 
peptide binding groove, these clashes were minimized for complexes with 
TCR orientations at the closer to parallel, rather than orthogonal, extremes 
of the range (unpublished data; Batuwangala, T., personal communication). 
This TCR orientation is exemplifi ed by that of the murine TCR 2C in the 
crystal structure of 2C-dEV8-H-2Kb (accession no. 2CKB ; reference 34), 
and after updating our assessment of possible docking orientations in the light 
of recent additions to the data base of TCR–pMHC complex structures, we 
selected this complex as the basis for a modeling exercise (as described in 
 Materials and methods). To generate docking models for the binding of the 
iNKT, 5E and 5B dsTCRs, onto human CD1d–α-GalCer, we fi rst superim-
posed each of the three dsTCRs onto the position of the TCR 2C in the 
crystal structure of the 2C-dEV8-H-2Kb complex; the pairwise superposi-
tions were based on the Vα chains and used program SHP (51). Subsequently, 
human CD1d–α-GalCer (accession no. 1ZT4; reference 16) was superim-
posed onto the position of dEV8-H-2Kb in the TCR–pMHC complex based 
on superposition of the α1/α2 domains. No attempt was made to optimize 
the interaction surfaces generated by these rigid body superpositions.
Structural fi gures were prepared with Bobscript (47), Raster3D (48), 
and Grasp (http://trantor.bioc.columbia.edu/grasp/).
Accession numbers. Coordinates and structure factors have been depos-
ited in the Protein Data Bank under accession nos. 2CDE (iNKT-TCR), 
2CDF (TCR 5E), and 2CDG (TCR 5B).
Online supplemental materials. FACS staining data for the two TCRs 5E 
and 5B is presented in Fig. S1. Composite OMIT electron density maps for 
the α chains (Fig. S2) and for the β chains (Fig. S3) of the structures of all three 
TCRs are shown. The conformations of Arg79, Ser76, and Asp80 in three 
published human and mouse CD1d structures are illustrated in Fig. S4, and 
the potential surfaces of the three TCRs calculated using GRASP are depicted 
in Fig. S5. Figs. S1–S5 are available at http://www.jem.org/cgi/content/
full/jem.20052369/DC1.
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